ACR Convergence 2025

October 24-29, 2025. Chicago, Illinois.

View by Number View by Title View Sessions

Sunday, October 26, 2025

10:30AM-12:30PM: Abstract Number: 0553

Modified A-Tool: An online self-screening tool for axial spondyloarthritis for patients with chronic back pain

(0522–0553) Spondyloarthritis Including Psoriatic Arthritis – Diagnosis, Manifestations, & Outcomes Poster I

10:30AM-12:30PM: Abstract Number: 0047

Monocyte Transcriptomic Signatures Uncover Potential Pathogenic Mechanisms of the APOL1 High Risk Genotype (HRG)

(0019–0048) Genetics, Genomics & Proteomics Poster

10:30AM-12:30PM: Abstract Number: 0237

Monogenic autoinflammatory diseases and undefined autoinflammatory syndrome in Western Mediterranean adults: clinical, genetic, and therapeutic insights

(0233–0279) Miscellaneous Rheumatic & Inflammatory Diseases Poster I

10:30AM-12:30PM: Abstract Number: 0150

Mortality in Anca-associated Vasculitis

(0145–0174) Epidemiology & Public Health Poster I

10:30AM-12:30PM: Abstract Number: 0235

Mortality Trends due to Hypertension Related Deaths in Elderly Patients with Inflammatory Polyarthropathy: A CDC WONDER Analysis of 21 Years

(0233–0279) Miscellaneous Rheumatic & Inflammatory Diseases Poster I

10:30AM-12:30PM: Abstract Number: 0009

MRT-6160, a VAV1-Directed Molecular Glue Degrader, Attenuates T and B Cell Effector Functions and Inhibits Disease Progression in a Spontaneous MRL-Faslpr Mouse Model

(0001–0018) B Cell Biology & Targets in Autoimmune & Inflammatory Disease Poster I

10:30AM-12:30PM: Abstract Number: 0268

Multicenter study and literature review of JAK inhibitor treatment in refractory uveitis due to different immune-mediated inflammatory pathologies

(0233–0279) Miscellaneous Rheumatic & Inflammatory Diseases Poster I

10:30AM-12:30PM: Abstract Number: 0485

Multicenter study on the use of Upadacitinib: Results in RA patients previously treated with Baricitinib

(0470–0505) Rheumatoid Arthritis – Treatment Poster I

10:30AM-12:30PM: Abstract Number: 0295

Multidimensional Analysis of Fatigue in Idiopathic Inflammatory Myopathies: Clinical, Psychological, and Sociodemographic Determinants

(0280–0305) Muscle Biology, Myositis & Myopathies – Basic & Clinical Science Poster I

10:30AM-12:30PM: Abstract Number: 0380

Multidimensional Health Assessment Questionnaire (MDHAQ)/RAPID3, is an Useful Tool to Assess Comorbid and Residual Fatigue in Rheumatoid Arthritis Patients

(0357–0386) Patient Outcomes, Preferences, & Attitudes Poster I

10:30AM-12:30PM: Abstract Number: 0705

Multimodal Imaging Evaluation of Patients with Raynaud’s Phenomenon meeting the Criteria for “Early” Systemic Sclerosis according to LeRoy versus Healthy Controls: a Prospective Cross-sectional study

(0671–0710) Systemic Sclerosis & Related Disorders – Clinical Poster I

10:30AM-12:30PM: Abstract Number: 0546

Multimorbidity clusters in psoriatic arthritis, psoriasis, and axial spondyloarthritis and their association with healthcare utilization: A population-based study

(0522–0553) Spondyloarthritis Including Psoriatic Arthritis – Diagnosis, Manifestations, & Outcomes Poster I

10:30AM-12:30PM: Abstract Number: 0385

Musculoskeletal Ultrasound Enhances Patient Insight and Clinical Decisions: A Multi-Center Study

(0357–0386) Patient Outcomes, Preferences, & Attitudes Poster I

10:30AM-12:30PM: Abstract Number: PP03

My Journey of Risk, Loss, and Hope: The Role of Multidisciplinary Collaboration in Managing Pregnancy with Takayasu Arteritis

(PP01-PP08) Patient Perspectives Poster

10:30AM-12:30PM: Abstract Number: 0220

National Implementation of a Medication Safety Dashboard to Improve HLA-B*58:01 Testing Among Allopurinol Users in the Veterans Health Administration

(0210–0232) Measures & Measurement of Healthcare Quality Poster I

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].